

# TG Therapeutics Inc (TGTX) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/T0FF5B77BCCEN.html>

Date: March 2021

Pages: 50

Price: US\$ 125.00 (Single User License)

ID: T0FF5B77BCCEN

## Abstracts

TG Therapeutics Inc (TGTX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

## Highlights

TG Therapeutics Inc (TG Therapeutics) is a biopharmaceutical company which acquires, develops and commercializes pharmaceutical products for the treatment of B-cell malignancies and autoimmune diseases. The company's approved product includes Ukoniq for the treatment of relapsed or refractory marginal zone lymphoma and relapsed or refractory follicular lymphoma. Ukoniq is approved in the US. Pipeline products of the company include Ublituximab for the treatment of chronic lymphocytic leukemia (CLL) and multiple sclerosis; Umbralisib for CLL; and Cosibelimab for B-cell cancers among others. The company also offers products and technologies for in-licensing, partnership, acquisition, and investment. The company has operations in the US and Australia. TG Therapeutics is headquartered in New York City, New York, the US.

### TG Therapeutics Inc Key Recent Developments

Mar 04,2021: TG Therapeutics to Present Results from the ULTIMATE I & II Phase 3 Trials Evaluating Ublituximab in Multiple Sclerosis at the Upcoming American Academy of Neurology 73rd Annual Meeting

Mar 02,2021: TG Therapeutics provides business update and reports fourth quarter and year-end 2020 financial results

Nov 09,2020: TG Therapeutics provides business update and reports third quarter 2020 financial results

Aug 10,2020: TG Therapeutics provides business update and reports second quarter 2020 financial results

May 14,2020: TG Therapeutics announces data presentations at upcoming medical meetings

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the

revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

**Note:** Some sections may be missing if data is unavailable for the company

## Contents

### **SECTION 1 - ABOUT THE COMPANY**

TG Therapeutics Inc - Key Facts  
TG Therapeutics Inc - Key Employees  
TG Therapeutics Inc - Key Employee Biographies  
TG Therapeutics Inc - Major Products and Services  
TG Therapeutics Inc - History  
TG Therapeutics Inc - Company Statement  
TG Therapeutics Inc - Locations And Subsidiaries  
Head Office  
Other Locations & Subsidiaries

### **SECTION 2 – COMPANY ANALYSIS**

Company Overview  
TG Therapeutics Inc - Business Description  
TG Therapeutics Inc - Corporate Strategy  
TG Therapeutics Inc - SWOT Analysis  
SWOT Analysis - Overview  
TG Therapeutics Inc - Strengths  
TG Therapeutics Inc - Weaknesses  
TG Therapeutics Inc - Opportunities  
TG Therapeutics Inc - Threats  
TG Therapeutics Inc - Key Competitors

### **SECTION 3 – COMPANY FINANCIAL RATIOS**

Financial Ratios - Capital Market Ratios  
Financial Ratios - Annual Ratios  
Performance Chart  
Financial Performance  
Financial Ratios - Interim Ratios  
Financial Ratios - Ratio Charts

### **SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES**

TG Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

TG Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021  
TG Therapeutics Inc, Recent Deals Summary

## **SECTION 5 – COMPANY’S RECENT DEVELOPMENTS**

Mar 04, 2021: TG Therapeutics to Present Results from the ULTIMATE I & II Phase 3 Trials Evaluating Ublituximab in Multiple Sclerosis at the Upcoming American Academy of Neurology 73rd Annual Meeting

Mar 02, 2021: TG Therapeutics provides business update and reports fourth quarter and year-end 2020 financial results

Nov 09, 2020: TG Therapeutics provides business update and reports third quarter 2020 financial results

Aug 10, 2020: TG Therapeutics provides business update and reports second quarter 2020 financial results

May 14, 2020: TG Therapeutics announces data presentations at upcoming medical meetings

May 11, 2020: TG Therapeutics provides business update and reports first quarter 2020 financial results

May 08, 2020: TG Therapeutics strengthens executive team with the addition of Owen A. O’Connor, MD, PhD, as chief scientific officer

Apr 29, 2020: TG Therapeutics Bolsters Board of Directors with the appointment of Sagar Lonial, MD

Mar 03, 2020: TG Therapeutics provides business update and reports fourth quarter and year-end 2019 financial results

## **SECTION 6 – APPENDIX**

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

TG Therapeutics Inc, Key Facts  
TG Therapeutics Inc, Key Employees  
TG Therapeutics Inc, Key Employee Biographies  
TG Therapeutics Inc, Major Products and Services  
TG Therapeutics Inc, History  
TG Therapeutics Inc, Subsidiaries  
TG Therapeutics Inc, Key Competitors  
TG Therapeutics Inc, Ratios based on current share price  
TG Therapeutics Inc, Annual Ratios  
TG Therapeutics Inc, Annual Ratios (Cont...1)  
TG Therapeutics Inc, Interim Ratios  
TG Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021  
TG Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021  
TG Therapeutics Inc, Recent Deals Summary  
Currency Codes  
Capital Market Ratios  
Equity Ratios  
Profitability Ratios  
Cost Ratios  
Liquidity Ratios  
Leverage Ratios  
Efficiency Ratios

## List Of Figures

### LIST OF FIGURES

TG Therapeutics Inc, Performance Chart (2016 - 2020)

TG Therapeutics Inc, Ratio Charts

TG Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

TG Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021



## I would like to order

Product name: TG Therapeutics Inc (TGTX) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/T0FF5B77BCCEN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/T0FF5B77BCCEN.html>